A medRxiv preprint from University College London researchers finds 2.9% of British adults used GLP-1 receptor agonists for weight loss in early 2025, led by Mounjaro, with nearly 4.9 million adults either recent users or interested. The authors say the gap between use and interest suggests unmet demand and urge monitoring for safe, equitable provision of the drugs.